Pirfenidone could offer ‘viable’ heart failure treatment
NIHR trial shows the lung drug could treat heart failure patients
Read More
Tag: Pirfenidone
NICE restricts NHS use of Roche’s IPF drug Esbriet
Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF), but only in those with moderate to severe forms of the disease.
Read More
NICE refuses to expand use of Roche’s IPF drug Esbriet
The National Institute for Health and Care Excellence (NICE) it remaining steadfast in its position that Roche’s Esbriet should only be funded by the NHS for patients with moderate forms of the fatal lung scarring disease idiopathic pulmonary fibrosis (IPF).
Read More
NICE says no to expanding scope of Roche’s IPF drug
Patients in England and Wales with the lung scarring disease idiopathic pulmonary fibrosis will have to wait until their disease has worsened before getting routine NHS access to Roche’s Esbriet.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
